News
Académie suisse des sciences techniques SATW
Bio-based business models for Switzerland?
The challenge remains substantial: 195 countries have committed to achieving carbon neutrality by 2050, implying that global annual CO₂ emissions must decline to approximately 9 to 10 billion tons, around one quarter of today’s levels. Against this backdrop, the bioeconomy has emerged as an increasingly prominent concept. Yet key questions remain: what pathways are realistic for Switzerland, and is a national bioeconomy strategy warranted? These questions will be explored in a dedicated issue of CHIMIA, jointly edited by SATW, SKB, and BFH, scheduled for publication in September 2027.
Académie suisse des sciences techniques SATW
News
Switzerland as a centre of innovation: International settlements as a driver of growth
Switzerland's innovative strength is recognised worldwide. However, the global competition for AI talent and technologies requires more than just good framework conditions - it needs targeted international networking.Académie Suisse des Sciences Médicales ASSM
News
Le Data Coordination Center de SPHN cherche du renfort
Le Swiss Personalized Health Network (SPHN) est une infrastructure nationale de données placée sous la responsabilité de l’ASSM en collaboration avec le SIB Institut Suisse de Bioinformatique. SPHN rend les données de santé interopérables et réutilisables pour la recherche en Suisse. Pour renforcer l’équipe Ethics, Legal and Social Implications (ELSI), nous cherchons de suite ou pour une date à convenir un.e responsable de projet. Le contrat (60–80%) sera dans un premier temps limité à la fin 2028, avec possibilité de prolongation.
Académie suisse des sciences techniques SATW
News
From foresight to first patients: HAYA Therapeutics enters the clinic
The Lausanne-based company HAYA Therapeutics, featured in the Technology Outlook showcase “The cryptic messages of our genome”, has reached two significant milestones in quick succession: the first cohort of participants has been dosed in a Phase 1 clinical trial of its lead candidate HTX-001, and the company has been named a “Disruptive Pioneer” in the 2026 Global Pharmaceutical Innovation and Invention Index published by IDEA Pharma. These developments underscore the relevance of the technology identified by SATW’s foresight activities.